Expression of Complement Receptor Type 1 on Erythrocytes in Autoimmune Diseases
- *Corresponding Author:
- Ya-Wen Cheng
Institute of Medicine, Chung Shan Medical University
No.110, Sec.1, Jianguo N.Rd., Taichung City 40201, Taiwan
E-mail: [email protected]
Received Date: December 13, 2013; Accepted Date: Januauary 15, 2014; Published Date: Januauary 22, 2014
Citation: Yang DH, Chen CH, Wei CC, Cheng YW (2014) Expression of Complement Receptor Type 1 on Erythrocytes in Autoimmune Diseases. J Mol Biomark Diagn 5:163. doi:10.4172/2155-9929.1000163
Copyright: © 2014 Yang DH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: The expression of complement receptor type 1 on different cells is associated with autoimmunity. Erythrocyte-Complement Receptor Type 1 (E-CR1) is a candidate for early diagnosis of Systemic Lupus Erythematosus (SLE) and assessed the roles of disease activity. We evaluated the expression of E-CR1 in the patients with SLE and other autoimmune diseases.
Methods: We conducted a cross-sectional investigation of 3 groups: (1) 36 patients with SLE; (2) 51 patients with other diseases including Rheumatoid Arthritis (RA), Sjögren’s syndrome, anti-phospholipid syndrome, Mixed Connective Tissue Disease (MCTD), Raynaud’s disease, ankylosing spondylitis, pulmonary Tuberculosis (TB); and (3) 26 healthy controls. Erythrocytes were analyzed by flow cytometry to determine levels of E-CR1.
Results: We found a significant reduction in the mean levels of E-CR1 in SLE patients compared to patients with healthy controls (1.79 ± 0.16 versus 3.82 ± 0.32, P<0.05). However, in patients with RA, MCTD, and TB, decreased E-CR1 levels were also observed. There was a statistically significant correlation between reduced levels of E-CR1 and SLE disease activity index (r=-0.326, P<0.05). The E-CR1 levels were inversely correlated with urine daily protein loss (r=-0.364, P<0.05).
Conclusions: Although E-CR1 levels may be a useful diagnostic marker for SLE, a possible limitation is that no significant differences in E-CR1 levels were observed among patients with SLE, those with MCTD and TB. Overall, E-CR1 levels in SLE patients are related to disease activity index and reflect renal clearance through urine daily protein loss.